CURX Stock Up 1,085% after 8-Day Win Streak
Curanex Pharmaceuticals (CURX) stock hit day 8 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 1,085% return. The company has gained about $2.2 Bil in value over the last 8 days, with its current market capitalization at about $201 Mil. The stock remains 1085.2% above its value at the end of 2024. This compares with year-to-date returns of 10.2% for the S&P 500.
CURX no company description provided to compress. Please provide the description for assistance.
Comparing CURX Stock Returns With The S&P 500
The following table summarizes the return for CURX stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | CURX | S&P 500 |
|---|---|---|
| 1D | 1.8% | -0.3% |
| 8D (Current Streak) | 1085.2% | 0.7% |
| 1M (21D) | 1085.2% | 2.2% |
| 3M (63D) | 1085.2% | 9.1% |
| YTD 2025 | 1085.2% | 10.2% |
| 2024 | 0.0% | 23.3% |
| 2023 | 0.0% | 24.2% |
| 2022 | 0.0% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 88 S&P constituents with 3 days or more of consecutive gains and 23 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 69 | 10 |
| 4D | 8 | 6 |
| 5D | 7 | 6 |
| 6D | 3 | 1 |
| 7D or more | 1 | 0 |
| Total >=3 D | 88 | 23 |
Key Financials for Curanex Pharmaceuticals (CURX)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-19,298 | $-0.3 Mil |
| Net Income | $-19,198 | $-0.4 Mil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-63,915 | $-0.1 Mil |
| Net Income | $-0.1 Mil | $-0.1 Mil |
While CURX stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.